NVAXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

NOVAVAX INC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$10.82−0.44 (-3.91%)

Close on Oct 19, 2026

Market cap: $1.78B
P/E (TTM): –
Dividend yield: –

NOVAVAX INC income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31
Revenue	1,123	682	984	1,982	1,146	476	19	34	31	15	36	31	21	22	15	0.34	–
Cost of Revenue	73	203	344	903	0	0	–	–	–	–	–	–	–	–	–	–	–
Gross Profit	1,050	479	640	1,079	1,146	476	–	–	–	–	–	–	–	–	–	–	–
Research & Development	342	391	738	1,235	2,535	747	114	174	168	238	163	94	59	27	18	28	26
Selling, General & Admin	157	337	469	489	–	–	–	–	–	–	–	–	–	–	–	–	–
General & Administrative	–	–	469	489	298	145	34	34	34	47	31	20	15	10	11	11	12
Advertising Expenses	1.90	34	92	84	8.90	–	–	–	–	–	–	–	–	–	–	–	–
Total Costs & Expenses	671	931	1,550	2,627	2,833	892	139	208	203	284	193	114	73	52	36	39	38
Operating Income	453	-249	-567	-645	-1,687	-417	-121	-174	-172	-269	-157	-84	-52	-30	-22	-38	-37
Interest Expense	23	20	14	20	21	15	14	14	14	13	0.24	0.16	0.16	0.03	0.01	0.01	0.79
Interest & Investment Income	30	37	20	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other Non-Operating Income	41	40	38	11	-6.83	14	-0.01	0.11	0.07	-0.03	-0.12	0	0.18	0.05	0.03	0.49	–
Merger & Restructuring Charges	–	–	15	0	–	–	–	–	–	3.60	–	–	–	–	–	–	–
Asset Impairment Charges	0	0	10	0	0	–	0	0	–	–	–	–	–	–	0.36	0.16	0.02
Gain (Loss) on Investments	–	–	–	–	–	–	–	–	–	0	0	0.62	0	0.88	–	–	0.85
Gain (Loss) on Sale of Assets	0	52	0	0	–	–	-0.09	0.06	-0.27	-0.37	-0.68	-0.53	0.03	0.03	–	-0.04	-0.02
Pretax Income	442	-177	-543	-654	-1,715	-418	-133	–	–	–	-157	-83	-52	-29	-19	-36	-40
Income Tax Expense	1.87	11	2.03	4.29	29	0	0	–	–	–	0	0	0.03	0	0.41	0.45	–
Net Income	440	-187	-545	-658	-1,744	-418	-133	-185	-184	-280	-157	-83	-52	-29	-19	-36	-40
Net Income to Common	440	-187	-545	–	–	–	–	–	–	–	–	–	–	-29	-19	-36	–
EPS (Basic)(per share)	2.72	-1.23	-5.41	-8.42	-23.44	-7.27	-5.51	-9.99	-12.56	-20.60	-12.00	-7.40	-6.20	-4.40	-3.40	-6.80	-9.40
EPS (Diluted)(per share)	2.58	-1.23	-5.41	-8.42	-23.44	-7.27	-5.51	-9.99	-12.56	-20.60	-12.00	-7.40	-6.20	-4.40	-3.40	-6.80	-9.40
Shares Outstanding (Basic, Weighted)(shares)	162	152	101	78	74	58	24	18	15	14	0.01	0.01	8.48	0.01	0.01	0.01	–
Shares Outstanding (Diluted, Weighted)(shares)	173	152	101	78	74	58	24	18	15	14	0.01	0.01	8.48	0.01	0.01	0.01	–
EBITDA	481	-201	-526	-616	-1,674	-412	-115	-167	-164	-261	-152	-79	-50	-28	-20	-37	-36

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 78.6%
Operating margin: -56.6%
Net margin: -59.9%
Return on equity, FY2025: -117.2%

Financial strength

Current ratio: 2.33
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 57.9%

Valuation

P/E ratio: –
Price to sales: 4.30
Price to book: –
Dividend yield: –